Novel roles for the Alzheimer's Disease (AD) risk gene, SORLA in neuroprotection in AD
阿尔茨海默病 (AD) 风险基因 SORLA 在 AD 神经保护中的新作用
基本信息
- 批准号:9788245
- 负责人:
- 金额:$ 68.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-30 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAlzheimer&aposs DiseaseAlzheimer&aposs disease riskAmyloid beta-ProteinAttenuatedBehavioralBindingBiochemicalBiological AssayBiological ProcessBrainCell modelCell surfaceCodeCognitiveCognitive deficitsDefectDiseaseDown SyndromeEtiologyExposure toFresh WaterFunctional disorderGenerationsGeneticHeadHippocampus (Brain)HydrozoaImpaired cognitionImpairmentInjectionsLate Onset Alzheimer DiseaseLibrariesLigand BindingLigandsMediatingModelingMusMutationNatural regenerationNerve DegenerationNeuritesNeurodegenerative DisordersNeuronsNeurotensinOnset of illnessPathologicPathway interactionsPeptidesPhysiologicalProcessProteolytic ProcessingProteomicsReceptor ActivationReportingResistanceRisk FactorsRoleSignal TransductionSynapsesTransgenic OrganismsVariantVertebral columnabeta toxicityage relatedagedcognitive functioncohortcombinatorialcrosslinkdensityexome sequencingextracellulargenetic risk factorgenome wide association studyin vivoinhibitor/antagonistinsightlimb regenerationmouse modelmutantneurite growthneuroprotectionneurotoxicnoveloverexpressionprotein protein interactionreceptorrepairedresponserisk variantsortilinsynaptic functiontrafficking
项目摘要
PROJECT SUMMARY
SORLA is a genetic risk factor for Alzheimer’s disease (AD) identified through GWAS analysis. Although
SORLA has been shown to regulate APP trafficking and consequent Aβ generation, a normal biological
function for SORLA remains elusive. It is likely that SORLA mediates additional neuroprotective effects in AD;
given that numerous mutational coding variants have been identified in SORLA through whole exome
sequencing in AD cohorts, these mutations may perturb SORLA-dependent neuroprotection, either through
functional protein-protein interaction or SORLA localization. Our preliminary results indicate that SORLA exerts
neuroprotective effects by binding and inhibiting the activation of putative Aβ receptors such as EphA4 to limit
synaptotoxic EphA4 activation and cognitive impairment with Aβ exposure. We also demonstrate a role for
SORLA in enhancing neurite outgrowth and regeneration, and that neurotrophic SORLA-binding ligands
(“SORLA ligands”) such as head activator (HA) and neurotensin (NT) peptides can mediate neurite
enhancement in a SORLA-dependent manner. Together, these results implicate new roles for SORLA in
enhancing synaptic function, neurite outgrowth and regeneration. The overall objective of this study is to
characterize mechanisms underlying SORLA-dependent resistance to Aβ synaptotoxicity, and to determine
whether enhancing SORLA-mediated neuroprotective mechanisms can ameliorate synaptic and cognitive
impairment in Aβ-dependent neurodegenerative models such as AD and Down Syndrome (DS).
Interactions between SORLA and receptors that modulate synaptic function such as EphA4 and TrkB, likely
drive SORLA-dependent neuroprotection with Aβ synaptotoxicity. Using a library comprising a comprehensive
set of SORLA-FLAG early and late onset AD-associated mutational variants, we will determine whether
mutations can affect SORLA interactions with TrkB, or neurotrophic ligands, and characterize differences in the
SORLA interactome in these variants. Given that SORLA can enhance synaptic function with Aβ exposure, we
will determine whether neurotrophic SORLA ligands can enhance synaptic LTP response and cognitive
function with stereotactic Aβ co-injection into the hippocampus. We also present evidence that similar to AD,
aged DS mouse models show similar EphA4 activation, indicating that EphA4 may drive some aspects of
synaptotoxicity in DS. We will determine whether transgenic SORLA overexpression in DS mouse models can
reduce synaptotoxic EphA4 activation and synaptic/cognitive impairment in a DS mouse model. Lastly, we will
determine whether SORLA neuroprotection through stereotactic delivery of SORLA ligands can reverse or
attenuate synaptic/cognitive impairment in AD mouse models and use bivalent SORLA/EphA4 crosslinking
peptides to determine whether reinforcing neuroprotective SORLA/EphA4 interactions can confer
synaptoprotective effects in AD mice. Together, these results will implicate new roles for SORLA in
neuroprotection and may implicate new modes of synaptic enhancement with Aβ toxicity.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Timothy Yikai Huang其他文献
Timothy Yikai Huang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Timothy Yikai Huang', 18)}}的其他基金
Elucidating a microgliaassociated role for SORLA in modulating AD pathogenesis
阐明 SORLA 在调节 AD 发病机制中的小胶质细胞相关作用
- 批准号:
10455261 - 财政年份:2022
- 资助金额:
$ 68.23万 - 项目类别:
Characterizing a potential role for TREM2 in modulating tau pathogenesis in response to Abeta
表征 TREM2 在响应 Abeta 调节 tau 发病机制中的潜在作用
- 批准号:
10360474 - 财政年份:2021
- 资助金额:
$ 68.23万 - 项目类别:
"A Novel Role for the UPR Component, ATF6 in AD-associated Neuroprotective Pathways"
“UPR 成分 ATF6 在 AD 相关神经保护途径中的新作用”
- 批准号:
10132964 - 财政年份:2019
- 资助金额:
$ 68.23万 - 项目类别:
"A Novel Role for the UPR Component, ATF6 in AD-associated Neuroprotective Pathways"
“UPR 成分 ATF6 在 AD 相关神经保护途径中的新作用”
- 批准号:
10563219 - 财政年份:2019
- 资助金额:
$ 68.23万 - 项目类别:
"A Novel Role for the UPR Component, ATF6 in AD-associated Neuroprotective Pathways"
“UPR 成分 ATF6 在 AD 相关神经保护途径中的新作用”
- 批准号:
10353397 - 财政年份:2019
- 资助金额:
$ 68.23万 - 项目类别:
Novel roles for the Alzheimer's Disease (AD) risk gene, SORLA in neuroprotection in AD
阿尔茨海默病 (AD) 风险基因 SORLA 在 AD 神经保护中的新作用
- 批准号:
10404609 - 财政年份:2018
- 资助金额:
$ 68.23万 - 项目类别:
Novel roles for the Alzheimer's Disease (AD) risk gene, SORLA in neuroprotection in AD
阿尔茨海默病 (AD) 风险基因 SORLA 在 AD 神经保护中的新作用
- 批准号:
9925791 - 财政年份:2018
- 资助金额:
$ 68.23万 - 项目类别:
Molecular pathobiology of soluble TREM2 in Alzheimer's disease
可溶性 TREM2 在阿尔茨海默病中的分子病理学
- 批准号:
10737172 - 财政年份:2017
- 资助金额:
$ 68.23万 - 项目类别: